PharmacoEconomics & Outcomes News 792, p36 - 2 Dec 2017 Regorafenib approved by NICE for advanced GIST The UK National Institute for Health and Care Excellence (NICE) has recommended regorafenib (Stivarga) for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST), reported Selina McKee in Pharma Times. Regorafenib will be available for routine funding within the NHS at the discount agreed with Bayer in a confidential patient access scheme, for adults with GIST with disease progression on, or who were intolerant to, previous imatinib and sunitinib therapy, and have an Eastern Cooperative Oncology Group performance status of 0 to 1. According to NICE, regorafenib meets the criteria for a life-extending end-of-life treatment, and has an estimated cost-effectiveness ratio of £44 000 per QALY gained compared with best supportive care. * National Health Service McKee S. Bayer’s Stivarga wins NICE approval for GIST Pharma Times : 20 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/ bayers_stivarga_wins_nice_approval_for_gist_1211984 803284556 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud